drugset / Trial / NCT02554955
A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of intravenous daclizumab in combination with oral mycophenolate mofetil and oral sirolimus in participants receiving a heart transplant, and at risk of impaired kidney function. The anticipated time on study treatment is 6 months, and the target sample size is 44 individuals.
Timeline
- Start
- 2004-02
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 1 g | Oral |
| Background | Sirolimus | Small molecule | 3 mg | Oral |
Indications
No indication recorded.